We are live on ! Find out more
NBIX icon

Neurocrine Biosciences
NBIX

391 hedge funds and large institutions have $9.56B invested in Neurocrine Biosciences in 2019 Q4 according to their latest regulatory filings, with 109 funds opening new positions, 137 increasing their positions, 103 reducing their positions, and 41 closing their positions.

New
Increased
Maintained
Reduced
Closed

166% more first-time investments, than exits

New positions opened: 109 | Existing positions closed: 41

65% more call options, than puts

Call options by funds: $93.9M | Put options by funds: $56.8M

33% more repeat investments, than reductions

Existing positions increased: 137 | Existing positions reduced: 103

18% more capital invested

Capital invested by funds: $8.09B → $9.56B (+$1.48B)

18% more funds holding

Funds holding: 332 → 391 (+59)

14% more funds holding in top 10

Funds holding in top 10: 7 → 8 (+1)

1.37% less ownership

Funds ownership: 98.02% → 96.65% (-1.4%)

Holders
391
Holders Change
+59
Holders Change %
+17.77%
% of All Funds
7.7%
Holding in Top 10
8
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+14.29%
% of All Funds
0.16%
New
109
Increased
137
Reduced
103
Closed
41
Calls
$93.9M
Puts
$56.8M
Net Calls
+$37.1M
Net Calls Change
+$33.9M

Top Buyers

1
Renaissance Technologies
Renaissance Technologies
New York
+$77M
2
BlackRock
BlackRock
New York
+$68.6M
3
State Street
State Street
Massachusetts
+$65.5M
4
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$58.7M
5
Ameriprise
Ameriprise
Minnesota
+$34M

Top Sellers

1
Fidelity Investments
Fidelity Investments
Massachusetts
-$138M
2
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$118M
3
HM
HealthCor Management
New York
-$71.9M
4
Wellington Management Group
Wellington Management Group
Massachusetts
-$68.6M
5
O
OrbiMed
New York
-$66.9M
Name Holding Trade Value Shares
Change 		Change in
Stake
AAM
201
Advisors Asset Management
Colorado
$1.36M +$70.9K +677 +6%
Man Group
202
Man Group
United Kingdom
$1.36M +$534K +5,099 +68%
BC
203
Brinker Capital
Pennsylvania
$1.31M +$9.32K +89 +0.7%
DBG
204
De Burlo Group
Massachusetts
$1.29M -$31.4K -300 -2%
CPC
205
Cookson Peirce & Co
Pennsylvania
$1.29M +$648K +6,193 +106%
DnB Asset Management
206
DnB Asset Management
Norway
$1.27M +$1.24M +11,829 New
Natixis Advisors
207
Natixis Advisors
Massachusetts
$1.26M +$119K +1,135 +11%
ARTA
208
A.R.T. Advisors
New York
$1.26M +$1.23M +11,743 New
NIPH
209
NN Investment Partners Holdings
Netherlands
$1.14M +$1.11M +10,588 New
Janney Montgomery Scott
210
Janney Montgomery Scott
Pennsylvania
$1.13M -$68.4K -653 -6%
LCG
211
Lisanti Capital Growth
New York
$1.12M +$143K +1,366 +15%
TAM
212
Tocqueville Asset Management
New York
$1.1M -$948K -9,055 -47%
CG
213
Colony Group
Massachusetts
$1.08M -$606K -5,789 -37%
GD
214
Grandfield & Dodd
New York
$1.08M +$56.5K +540 +6%
Qube Research & Technologies (QRT)
215
Qube Research & Technologies (QRT)
United Kingdom
$1.07M +$1.04M +9,960 New
RSC
216
Red Spruce Capital
Pennsylvania
$1.07M +$1.04M +9,926 New
Principal Financial Group
217
Principal Financial Group
Iowa
$1.07M -$4.94M -47,178 -83%
TC
218
TwinBeech Capital
New York
$1.02M +$997K +9,526 New
AIM
219
Aigen Investment Management
New York
$999K +$974K +9,298 New
GC
220
Globeflex Capital
California
$996K +$970K +9,268 New
HMS
221
Hanseatic Management Services
New Mexico
$972K +$947K +9,047 New
MWVC
222
Morgens Waterfall Vintiadis & Co
New York
$967K +$942K +9,000 New
Walleye Capital
223
Walleye Capital
New York
$949K +$648K +6,191 +235%
UONDDL
224
University of Notre Dame du Lac
Indiana
$935K -$71.7K -685 -7%
NIT
225
NumerixS Investment Technologies
British Columbia, Canada
$935K +$607K +5,800 +200%
7 8
9
10 11

NBIX Hedge Fund Activity: Q4 2019 in Review

391 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Neurocrine Biosciences (NBIX) for Q4 2019, worth a combined $9.56B — up 18% from $8.09B a quarter earlier.

Buyers outnumbered sellers: 109 funds opened new NBIX positions and 41 closed out — a net gain of 68 holders — while 137 added to existing stakes and 103 trimmed.

The largest buyer was Renaissance Technologies, adding an estimated $77M. The largest seller was Fidelity Investments, cutting an estimated $138M.

  • 391 institutional investors held Neurocrine Biosciences (NBIX) as of Q4 2019, up from 332 in Q3 2019.
  • Funds reported $9.56B of Neurocrine Biosciences stock for Q4 2019, up 18% quarter-over-quarter.
  • 109 funds opened new Neurocrine Biosciences positions in Q4 2019 and 41 closed out, a net change of +68 holders.
  • The largest Neurocrine Biosciences buyer in Q4 2019 was Renaissance Technologies, an estimated $77M added.
  • The largest Neurocrine Biosciences seller in Q4 2019 was Fidelity Investments, an estimated $138M sold.

Based on aggregated 13F filings for Q4 2019.